OBJECTIVE: Ubiquitin C-terminal hydrolase (UCH-L1), also called neuronal-specific protein gene product (PGP 9.3), is highly abundant in neurons. To assess the reliability of UCH-L1 as a potential biomarker for traumatic brain injury (TBI) this study compared cerebrospinal fluid (CSF) levels of UCH-L1 from adult patients with severe TBI to uninjured controls; and examined the relationship between levels with severity of injury, complications and functional outcome.

DESIGN: This study was designed as prospective case control study.

PATIENTS: This study enrolled 66 patients, 41 with severe TBI, defined by a Glasgow coma scale (GCS) score of

SETTING: Two hospital system level I trauma centers.

MEASUREMENTS AND MAIN RESULTS: Ventricular CSF was sampled from each patient at 6, 12, 24, 48, 72, 96, 120, 144, and 168 hrs following TBI and analyzed for UCH-L1. Injury severity was assessed by the GCS score, Marshall Classification on computed tomography and a complicated postinjury course. Mortality was assessed at 6 wks and long-term outcome was assessed using the Glasgow outcome score 6 months after injury. TBI patients had significantly elevated CSF levels of UCH-L1 at each time point after injury compared to uninjured controls. Overall mean levels of UCH-L1 in TBI patients was 44.2 ng/mL (+/-7.9) compared with 2.7 ng/mL (+/-0.7) in controls (p <0.001). There were significantly higher levels of UCH-L1 in patients with a lower GCS score at 24 hrs, in those with postinjury complications, in those with 6-wk mortality, and in those with a poor 6-month dichotomized Glasgow outcome score.

CONCLUSIONS: These data suggest that this novel biomarker has the potential to determine injury severity in TBI patients. Further studies are needed to validate these findings in a larger sample.

Papa L, Akinyi L, Liu MC, Pineda J, Tepas J, Oli MW, Zheng W, Robinson G, Robicsek SA, Gabrielli A, Heaton S, Hannay J, Demery J, Brophy G, Layon J, Robertson C, Hayes RL, Wang KK.

From the Department of Emergency Medicine (LP, JT), Orlando Regional Medical Center, 86 W. Underwood (S-200), Orlando, Florida; Banyan Biomarkers Inc. (LA, MCL, MWO, GR, RLH, KKWW), Alachua, Florida; Department (JP), Washington University, St. Louis, Missouri; Center for Traumatic Brain Injury Studies (WZ, SAR, AG, SH, JL), University of Florida, Gainesville, Florida; Department (JH), University of Houston, Houston, Texas; Department (JD), VA Hospital, Gainesville, Florida; Department (GB), Virginia Commonwealth University, Richmond, Virginia; Department (CR), Baylor College of Medicine, Houston, Texas. 

PMID: 19726976 [PubMed - as supplied by publisher]

Sobre a REDE-TB

A Rede Brasileira de Pesquisa em Tuberculose (REDE-TB) é uma Organização Não Governamental (ONG) de direito privado sem fins lucrativos, preocupada em auxiliar no desenvolvimento não só de novos medicamentos, novas vacinas, novos testes diagnósticos e novas estratégias de controle de TB, mas também na validação dessas inovações tecnológicas, antes de sua comercialização no país e/ou de sua implementação nos Programa de Controle de TB no País.



E-mail: redetb.rp@gmail.com

Tel: +55 (21)3938 - 2426
Tel/ Fax: +55 (21)3938 - 2431.

Endereço: Avenida Carlos Chagas Filho, 791, Cidade Universitária - Ilha do Fundão, Rio de Janeiro, RJ - Brasil. CEP: 21941-904

Assine a newsletter da REDE-TB

Curta REDE-TB no Facebook